Emerging data suggest Retatru tide , a dual activator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , could offer a promising step forward for obesity management . Early patient trials have indicated substantial losses in abdominal tissue, conceivably surpassing current weight-loss medications . Nevertheless , further assess